Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | CPN1 | P15169 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723903 | 1.00 | NPSR1 (0.47) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL11862175 | 0.86 | TP53 (0.40) | NPSR1NOS1CPN1CPB2ALDH1A1 | |
| SCHEMBL14320269 | 0.85 | NOS1 (0.52) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL13724064 | 0.85 | NOS1 (0.52) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL19526913 | 0.84 | NOS1 (0.55) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL14321296 | 0.81 | NOS1 (0.47) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL14321297 | 0.81 | NOS1 (0.47) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL14320290 | 0.80 | NOS1 (0.46) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL13724211 | 0.80 | NOS1 (0.46) | NPSR1NOS1PBRM1CPN1CPB2 | |
| SCHEMBL8036958 | 0.78 | CA1 (0.44) | NPSR1ALDH1A1CA1CA2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NPSR1 3382/4885NOS1 1289/4885PBRM1 4554/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NPSR1 4201/4885NOS1 2068/4885PBRM1 4347/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NPSR1 3382/4885NOS1 1289/4885PBRM1 4554/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | NPSR1 3382/4885NOS1 1289/4885PBRM1 4554/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | NPSR1 4010/4885NOS1 1989/4885PBRM1 3429/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NPSR1 3331/4885NOS1 1266/4885PBRM1 4443/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NPSR1 3331/4885NOS1 1266/4885PBRM1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.